Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [3] Partnership Announcement - Lucid Diagnostics has entered into its first concierge medicine contract with LEAA Health, allowing LEAA Health's membership-based patients access to EsoGuard esophageal precancer testing on a cash-pay basis. This partnership aims to enhance personalized care services [1][2] Market Potential - The concierge medicine market in the United States is projected to reach $10.9 billion by 2032, indicating a growing demand for personalized, prevention-focused healthcare services [2] Product Offering - EsoGuard is described as a groundbreaking approach to esophageal precancer detection, enabling early identification of potential issues when intervention can be most effective. The test is part of LEAA Health's enhanced personalized care offerings [2] Strategic Goals - Lucid aims to drive contractually guaranteed revenue through its cash-pay program targeting concierge medicine, while also working to secure Medicare and commercial coverage for its products [2]